SCHEMBL23949229

SCHEMBL23949229

Cc1cc(C(=O)c2cc(C#N)ccc2-c2ncc(CCN)cn2)cc(N2CCOCC2)n1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.41
AKT1 P31749 3/20 0.39
PIK3CA P42336 3/20 0.39
MTOR P42345 2/20 0.39
EGLN1 Q9GZT9 3/20 0.39
SLC6A9 P48067 1/20 0.37
SLC6A5 Q9Y345 1/20 0.37
HTT P42858 2/20 0.36
RAB9A P51151 1/20 0.36
ATM Q13315 1/20 0.36
FASN P49327 5/20 0.36
MAPT P10636 1/20 0.36
LMNA P02545 2/20 0.36
TSHR P16473 2/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
USP2 O75604 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30257143 1.00 PPARG (0.41) PPARGAKT1PIK3CAMTOREGLN1
SCHEMBL25555593 0.93 PPARG (0.42) PPARGAKT1PIK3CAMTOREGLN1
SCHEMBL25555575 0.88 PPARG (0.41) PPARGAKT1EGLN1SLC6A9SLC6A5
SCHEMBL25555664 0.87 PIK3CA (0.44) AKT1PIK3CAMTORHTTRAB9A
SCHEMBL23949225 0.85 AKT1 (0.44) PPARGAKT1EGLN1
SCHEMBL25555814 0.85 LMNA (0.37) AKT1PIK3CAEGLN1HTTMAPT
SCHEMBL25555639 0.83 PPARG (0.41) PPARGAKT1PIK3CAMTOREGLN1
SCHEMBL25555541 0.83 PPARG (0.41) PPARGEGLN1SLC6A9SLC6A5FASN
SCHEMBL25555885 0.83 HTT (0.38) PPARGPIK3CAEGLN1HTTRAB9A
SCHEMBL25058722 0.82 ALOX5 (0.38) PPARGPIK3CAMTOREGLN1SLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115996910-A Aryl or heteroaryl derivatives 帝人制药株式会社 2023-04-21 CN claimed
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2023-06-01 US disclosed
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2023-06-01 US disclosed
CN-115996910-A Aryl or heteroaryl derivatives 帝人制药株式会社 2023-04-21 CN disclosed
EP-4137481-A1 ARYL OR HETEROARYL DERIVATIVE Teijin Pharma Limited (JP) 2023-02-22 EP disclosed
WO-2021210650-A1 ARYL OR HETEROARYL DERIVATIVE 帝人ファーマ株式会社 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE ARRB1, NR3C2, TRPC6 PPARG 2184/4885AKT1 1144/4885PIK3CA 3474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.